Drug Pricing

Commentary

Diversifying America’s supply chains point to a more prosperous economic future

Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Commentary

Democrats’ Price Controls Undermine Biden’s Cancer Moonshot

Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Commentary

Grave Mistake to Fix Drug Prices Without Esteem for Their Value

Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Commentary

How to give patients a right to save on health care

Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
Drug Pricing

NEW BRIEF: Empowering Providers to Promote Healthcare Innovation

These reforms include:   Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Commentary

Price Controls, Publicly Funded Insurance Won’t Deliver Value

On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary

An Effective Treatment for Alzheimer’s, But Only if ICER Allows It

Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
Drug Prices

NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care

SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Commentary

What Is the Value of the Interchangeability Designation for a Biosimilar?

By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Blog

Health Care Priorities for Next Congress

Election day approaches quickly. But no matter who wins come November, Americans must urge Congress to prioritize health care policy. Health care costs are consistently rising which endangers lives because costs can constrain patients from receiving needed care. Pandemic exigencies further highlighted shortcomings in our health care system. Before pandemic ...
Commentary

Diversifying America’s supply chains point to a more prosperous economic future

Rep. Cathy McMorris Rodgers, R-Wash., the chair of the powerful House Energy and Commerce Committee, recently warned that the United States is “dangerously dependent” on Chinese supply chains, especially for the raw materials used to make medicines. Her statement reflects the genuine worries of industry experts and ordinary Americans. If ...
Commentary

Democrats’ Price Controls Undermine Biden’s Cancer Moonshot

Last night’s State of the Union address was a festival of cognitive dissonance. President Biden proudly lauded the price controls that Democrats have begun implementing on prescription drugs as part of last August’s Inflation Reduction Act. He also touted his administration’s Cancer Moonshot, which aims to halve the cancer death rate ...
Commentary

Grave Mistake to Fix Drug Prices Without Esteem for Their Value

Democrats remain fixated on prescription drug prices. Last August, they managed to include price controls on drugs dispensed through Medicare in the Inflation Reduction Act. And they’re not done meddling. Earlier this month, Rep. Lloyd Doggett, D-Texas, called on President Biden to unilaterally suspend drug patents in order “to address the crisis ...
Commentary

How to give patients a right to save on health care

Shopping around has never been easier. With a few clicks, consumers can easily find deals on flights, get multiple quotes on car insurance or price-match items in their local shopping mall. Yet when it comes to spending money on something really important — their health — consumers are largely in ...
Drug Pricing

NEW BRIEF: Empowering Providers to Promote Healthcare Innovation

These reforms include:   Implementing the insurance reforms discussed in Part 5 that, from a provider perspective, will incentivize the creation of innovative payment models. New payment models create opportunities to better align the incentives of providers and patients. Implementing regulatory reforms that include eliminating certificate of need laws, scope ...
Commentary

Price Controls, Publicly Funded Insurance Won’t Deliver Value

On Dec. 14, the Centers for Medicare and Medicaid Services (cms.gov) released their latest estimate of the country’s annual healthcare tab. For the second straight year, U.S. healthcare spending topped $4 trillion. In 2021, health spending accounted for more than 18% of U.S. GDP. Progressives tend to cite numbers like these ...
Commentary

An Effective Treatment for Alzheimer’s, But Only if ICER Allows It

Three days before Christmas, the Institute for Clinical & Economic Review (ICER) is scheduled to publish a draft assessment of two promising treatments for Alzheimer’s disease. Unfortunately for the millions of Americans living with this fatal illness, it is likely that ICER will be giving lumps of coal, not gifts, ...
Drug Prices

NEW STUDY: 340B Providers Reap Big Profits, Should Be Reformed to Ensure At-Risk Patients Receive Affordable Care

SACRAMENTO – The broken 340B program, designed to provide affordable care for at-risk patients, creates massive profits for providers without necessarily improving patient health outcomes and should be reformed, finds a new issue brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute. ...
Commentary

What Is the Value of the Interchangeability Designation for a Biosimilar?

By Wayne Winegarden, Robert Popovian & Peter Pitts Biosimilars, to date, have achieved the promise of reducing prices and drug spending in the United States. The unquestioned safety and efficacy of biosimilars have given providers, patients, and employers, amongst many others, the confidence that savings will be even more robust as we ...
Blog

Health Care Priorities for Next Congress

Election day approaches quickly. But no matter who wins come November, Americans must urge Congress to prioritize health care policy. Health care costs are consistently rising which endangers lives because costs can constrain patients from receiving needed care. Pandemic exigencies further highlighted shortcomings in our health care system. Before pandemic ...
Scroll to Top